














Pseudotyped viruses Primary culture samples
Subtype Tested strains MeanIC80* Neutralized (%)** ART Tested samples MeanIC80* Neutralized (%)**
A1 13 0.09 53.8 off 77 0.80 76.6
B 26 0.13 88.5 on 102 0.58 78.4
C 211 0.20 61.1
D 5 0.04 20.0
G 7 0.06 85.7
01_AE 16 n.d. 0.0
02_AG 9 0.79 77.8
07_BC 5 0.04 80.0
08_BC 2 0.97 100.0
A1C 4 n.d. 0.0
A1D 2 0.17 50.0
A1CD 1 0.06 100.0
CD 5 0.11 80.0
All 306 0.18 60.5 All 179 0.67 77.7
* Geometric mean of neutralized viruses.
** IC80 < 20 g/ml.
Supplementary Figure 1. HIV-1 neutralizing activity of 10-1074
(a) Summary of 10-1074 neutralizing in vitro activity based on 306 HIV-1 pseudotyped viruses comprising 
13 subtypes and recombinant forms. Data were retrieved from the ‘CATNAP Database’ (Yoon et al., 
Nucleic Acid Res 2015) and analyzed using ‘AntibodyDatabase’ by Anthony West (West et al., PNAS 
2013). Mean IC80-values are color-coded (dark red: < 0.1 µg/ml; light red: 0.1 - 0.49 µg/ml, and orange: 
0.5 - 1 µg/ml). n.d.: not determined. (b) 10-1074 neutralizing in vitro activity of 179 primary culture 
samples obtained by viral outgrowth assay from HIV-1-infected subjects living in the U.S. or Germany. 77 
subjects were off and 102 were on antiretroviral therapy (ART; values partially obtained from previous 
measurements, Scheid and Horwitz et al., Nature 2016). Neutralizing activity was determined by the 
TZM.bl neutralization assay. (c) Illustration of the fraction (i.e., % coverage; y-axis) of HIV-1 isolates/
cultures that are neutralized at a given IC80 (μg/ml; x-axis) using the data sets from (a) and (b).
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87   Subjects screened
HIV-1-infected43
Screen Failure
9    No longer interested
8    Did not meet inclusion criteria
      7   Low CD4+ T cell count
      1   High viral load
6    Met exclusion criteria
      3   Investigator’s discretion for
           other medical condition
           1   Seizures/Encephalitis
           1   Active syphilis
           1   Abnormal EKG
      1   Hepatitis B
      1   Hepatitis C
      1   Elevated bilirubin
1    Scheduling difficulties




16  No longer interested
12  Met exclusion criteria
      4   Low hemoglobin
      3   History of autoimmune
           disease (pos. ANA)
      2   Elevated AST
      
1   Elevated bilirubin
      
2   Investigator’s discretion for
     other medical condition
           
1   Uncontrolled hypertension
1   Positive RPR
 2  Unable to complete blood draw
































 Supplementary Figure 2. Subject enrollment and study design
A total of 87 HIV-1-infected and -uninfected subjects were screened for study participation. In both cohorts, 
10-1074 was sequentially administered at increasing doses of 3 mg/kg (groups 1A and 2A), 10 mg/kg 
(groups 1B and 2B), or 30 mg/kg (groups 1C-D and 2C-D) to HIV-1-infected (groups 1) and HIV-1-uninfect-
ed (groups 2) participants. Of a total of 87 subjects screened, 19 HIV-1-infected and 14 -uninfected partici-
pants were enrolled.
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Supplementary Figure 3. Viremia and 10-1074 serum levels in HIV-1-infected subjects 
(a, b) HIV-1 RNA plasma copies (solid red line) and 10-1074 serum concentration determined by TZM-bl 
assay (blue line) after a single intravenous infusion of 10-1074 at a dose of 10 mg/kg (a) or 30 mg/kg (b). 
Arrows and dashed red lines indicate time of viral rebound, defined as an increase of HIV-1 RNA of at least 
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Supplementary Figure 4. Phylogenetic analysis of plasma env sequences obtained before and after 
10-1074 infusion 
(a) Maximum-likelihood phylogenetic trees of plasma-derived env sequences from subjects sampled 
before (Day 0/pre-infusion visit) and at different timepoints (Wk 1, Wk 2, Wk 4, Wk 8, Wk 12, Wk 16, Wk 
20, Wk 24) after 10-1074 infusion. Black asterisks indicate nodes with boostrap support   (b) Amino 
acid alignment of HxB2 positions 324-336 of SGS sequences. Columns one and two indicate the time point 
sampled and number of sequences, respectively. Yellow boxes denote changes from day 0 majority 
variant. Light blue lines indicate intact potential N-linked glycosylation motifs at either N332 or N334 (when 
present). (c) Pseudovirus neutralization data of selected subjects’ plasma envelope sequences. Shown are 
IC80 values in (µg/ml) of 5 different monoclonal antibodies that are currently in or planned for clinical testing.



































































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
1 Day0 - 0.024 0.054 0.544 2.270 >50
2 Day0 - 0.015 0.326 0.171 0.449 >50
3 Day0 - 0.037 8.898 0.132 0.446 >50
4 Day0 - 0.033 0.219 0.055 0.303 >50
5 Day0 - 0.014 0.026 0.141 1.109 >50
6 Wk4 N332T >50 >50 0.087 0.381 >50
7 Wk4 S334R >50 >50 0.041 0.192 >50
8 Wk4 S334G >50 >50 0.034 0.162 >50
9 Wk4 N332I >50 >50 0.205 0.336 >50






















































Supplementary Figure 4 continued (1HB2) 























10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
11 Day0 - 0.029 0.136 0.074 0.483 >50
12 Day0 - 0.026 0.099 0.070 0.363 >50
13 Day0 - 0.030 0.124 0.064 0.630 >50
14 Day0 - 0.024 0.172 0.071 0.492 >50
15 Day0 - 0.026 0.172 0.079 0.344 >50
16 Wk4 S334G >50 >50 0.060 0.529 >50
17 Wk4 N332S >50 >50 0.053 0.273 >50
18 Wk4 shift** >50 >50 0.045 0.592 >50
19 Wk4 S334R >50 >50 0.061 0.443 >50
20 Wk4 shift** >50 >50 0.060 0.311 >50


































































































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
22 Day0 - 0.115 0.038 0.320 5.104 1.698
23 Day0 - 0.048 0.048 0.105 1.034 4.876
24 Day0 - 0.160 0.092 0.435 5.752 1.294
25 Day0 - 0.098 0.035 0.431 4.862 2.323
26 Wk4 N332D >50 >50 0.660 6.231 1.828
27 Wk4 D325G >50 >50 0.417 4.568 1.314
28 Wk4 N332K >50 >50 0.457 5.854 2.348
29 Wk4 S334N >50 >50 0.438 3.831 1.153













































Supplementary Figure 4 continued (1HC1) 
#
seq
10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
31 Day0 - 1.104 0.741 0.657 0.891 >50
32 Day0 N332T >50 4.575 0.017 0.084 >50
33 Day0 - 1.371 1.074 0.568 0.667 >50
34 Day0 - 1.179 1.163 0.454 0.336 >50
35 Day0 - 0.797 0.330 0.880 1.075 >50
36 Day0 N332T 10.01 0.391 0.013 0.053 >50
37 Wk4 N332S >50 >50 0.993 1.524 >50
38 Wk4 S334N >50 >50 1.203 1.261 >50
39 Wk4 - 1.498 0.983 0.656 0.716 >50
40 Wk4 N332T >50 >50 0.398 0.457 >50
41 Wk4 - 1.481 1.166 0.818 0.618 >50


















































































































Supplementary Figure 4 continued (1HC2) 
10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
43 Day0 - 0.494 0.469 0.760 2.673 0.017
44 Day0 - 0.257 0.219 1.475 1.174 0.080
45 Day0 - 0.068 0.047 >50 1.325 0.914
46 Day0 - 0.090 0.044 >50 7.175 0.018
47 Day0 - 0.090 0.046 0.083 0.096 0.020
48 Day0 - 0.109 0.050 0.054 0.306 0.017
49 Wk4 S334N >50 >50 6.513 1.728 0.007
50 Wk4 S334N >50 >50 0.122 0.061 0.003
51 Wk4 N332K >50 >50 5.952 3.721 0.010
52 Wk4 N332T >50 >50 0.175 0.727 0.012
53 Wk4 N332K >50 >50 >50 7.683 0.008






















































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
55 Day0 - 0.531 0.104 3.571 2.107 0.008
56 Day0 - 0.836 0.202 1.041 1.256 0.020
57 Day0 - 0.514 0.117 42.56 2.273 0.015
58 Day0 - 0.704 0.254 0.156 0.776 0.013
59 Day0 - 0.946 0.213 0.630 1.679 0.064
60 Wk4 S334N >50 >50 0.816 1.667 0.053
61 Wk4 N332K >50 >50 9.426 3.600 0.041
62 Wk4 N332S >50 >50 0.634 1.095 0.012
63 Wk4 S334N >50 >50 5.043 2.245 0.058































































































Supplementary Figure 4 continued (1HD1) 
#
seq
10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
65 Day0 - 0.102 0.034 1.313 9.558 2.654
66 Day0 - 0.038 0.016 0.248 3.241 0.534
67 Day0 - 0.029 0.011 0.064 0.588 0.930
68 Day0 - 0.066 0.026 0.116 0.681 3.731
69 Day0 - 0.046 0.021 0.351 2.098 2.104
70 Wk4 S334N >50 >50 0.350 1.751 1.817
71 Wk4 S334R >50 >50 0.311 1.585 1.185
72 Wk4 S334N >50 >50 0.177 0.583 2.111
73 Wk4 N325K >50 >50 0.467 4.299 1.487
















































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
75 pre N332T >50 >50 0.018 0.210 10.96
76 pre N332T >50 >50 0.003 0.014 >50
77 pre N332T >50 >50 0.022 0.126 13.84



































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
79 Day0 - 0.021 0.008 1.895 9.346 >50
80 Day0 - 0.025 0.020 1.298 1.968 >50
81 Day0 - 0.027 0.020 0.628 2.199 >50
82 Day0 - 0.017 0.011 0.580 1.434 >50
83 Day0 - 0.027 0.014 0.517 1.912 >50
84 Wk4 S334R >50 0.557 0.354 2.772 >50
85 Wk4 N332K >50 0.214 0.947 2.219 >50
86 Wk4 N332D >50 0.199 0.794 7.741 >50
87 Wk4 N332D >50 0.077 0.720 2.852 >50


















































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
89 Day0 - 0.162 0.040 >50 0.733 1.476
90 Day0 - 0.159 0.045 0.131 0.622 1.204
91 Day0 - 0.130 0.040 0.118 0.783 1.629
92 Day0 - 0.191 0.038 0.112 0.627 1.432
93 Day0 - 0.123 0.055 0.117 0.783 1.463
94 Wk4 S334R >50 >50 0.168 0.658 1.436
95 Wk4 S334N >50 >50 0.149 0.961 1.176
96 Wk4 N332S >50 >50 48.18 0.891 1.530
97 Wk4 S334G >50 >50 0.158 0.886 1.135
98 Wk4 N332K >50 >50 0.103 0.606 1.518


























































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
100 Day0 - 0.097 0.040 0.748 5.167 0.432
101 Day0 - 0.187 0.063 0.780 3.761 >50
102 Day0 - 0.117 0.069 0.783 3.371 0.359
103 Day0 - 0.096 0.046 0.750 2.589 0.918
104 Wk4 S334A >50 >50 0.839 3.452 0.375
105 Wk8 S334F >50 >50 1.021 4.718 0.445
106 Wk8 - 0.130 0.037 3.342 0.205 0.504















































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
108 Day0 - 0.006 0.005 0.281 3.195 >50
109 Day0 - 0.024 0.100 0.048 0.664 >50
110 Day0 - 0.016 0.037 0.166 2.447 >50
111 Day0 - 0.155 0.303 0.595 3.949 >50
112 Day0 - 0.007 0.013 0.212 2.013 >50
113 Wk4 N332S >50 >50 0.922 2.858 >50
114 Wk4 S334G >50 >50 0.048 0.369 >50
115 Wk4 N332K >50 >50 0.102 0.819 >50
116 Wk4 S334N >50 >50 0.136 0.583 >50
117 Wk4 S334R >50 >50 0.126 1.365 >50































































10-1074 PGT121 3BNC117 VRC01
PGDM
1400
# TP Mutation IC80 IC80 IC80 IC80 IC80
119 Day0 325E >50 >50 0.087 1.587 0.873
120 Day0 325E >50 >50 0.147 2.221 0.625

































































































Supplementary Figure 5. Statistical analysis of viral load changes in the 10-1074-sensitive HIV-1-infected 
30 mg/kg dose group
The significance of viral load changes after 10-1074 infusion was analyzed using simultaneous confidence 
bands. Each blue dot represents a viral load measurement of a responder that received the 30 mg/kg dose. 
Simultaneous confidence bands were computed with the R package locfit (version 1.5-9.1) using the Gauss-
ian family for the local likelihood function. The solid line represents the regression fit and the dashed lines 
show the simultaneous confidence bands at 95% certainty level. The simultaneous confidence bands 
exclude zero from about 3 days after infusion to about 27 days after infusion, demonstrating that there is a 
significant effect on viral load reduction during that time period.




















Supplementary Figure 6. CD4+ and CD8+ T cell counts 
(a-b) Absolute counts (left panels) and relative frequencies (right panels) of CD4+ T cells (a) and CD8+ T 
cells (b) before, and 1 and 8 weeks after 10-1074 infusion. (c) CD4/CD8 ratio before, and 1 and 8 weeks 
after 10-1074 infusion. Mean is indicated by the red line and bars represent standard deviation. Differences 
between time points were tested by repeated measures one-way ANOVA. If significant, Dunnett’s test was 



























































































Supplementary Figure 7. Nucleotide alignment of N332 glycan region in study participants
Depicted are the different nucleotide motifs encoding the N332 glycan region (positions 332-334) in each 
subject at Day 0 (d0, **pre-infusion for 1HD2) and four weeks after infusion of 10-1074 (*wk4 and wk8 for 
1HD6K, 1HD10K). To the left of each motif is the number of sequences matching a particular motif. Trans-
lation of the 9-nt span is shown below each nucleotide sequence. Yellow boxes highlight nucleotide chang-
es away from the Day 0 majority variant. Red boxes highlight amino acid changes that disrupt the potential 
N-linked glycosylation site (PNGS) at position 332, while tourquoise boxes highlight non-synonymous 
changes that do not disrupt the PNGS. Subjects that harbored 10-1074-sensitive viruses on day 0 are 



































































































































































Supplementary Figure 8. Relative frequency of 10-1074 escape mutations in plasma envelope sequenc-
es 1 week after infusion
(a) Pie charts illustrate the relative abundance of particular amino acid mutations at envelope residues 325, 
332, and 334 as analyzed by SGS. Type of escape mutation indicated by color code. (b) Correlation of time 
to viral rebound (x-axis) and the percentage of viruses mutated at 325, 332 or 334 (y-axis). Colors of dots 
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# seq         of total 325 332-334
E
Supplementary Figure 9. SMRT sequencing of subjects 1HB3 and 1HC2
Maximum-likelihood phylogenetic trees of full-length plasma envelope single molecule real time sequenc-
ing of subjects 1HB3 (a) and 1HC2 (c) obtained on Day 0 and Week 4 after 10-1074 infusion. Branches 
show high-quality consensus reads (HQCSs) with their respective copy number visualized by the size of 
the circle. Tables in (b) and (d) summarize obtained number of filtered reads (# seq) for sequence variants 
in envelope region 324-334 and the relative frequency of each variant (of total) for the two subjects, respec-
tively. Arrow in (b) highlights Day 0 minor variant carrying a 332NIN334 mutation.
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a      Demographics of HIV-1-infected participants enrolled in groups 1A-1D 
b      Demographics of HIV-1-negative participants enrolled in groups 2A-2D
Supplementary Table 1. Study participant demographics
Study ID 10-1074 dose Age        (years) Gender Race
2HA1 3 mg/kg 41 Male Black
2HA2 3 mg/kg 58 Male Black
2HA3 3 mg/kg 43 Female White
2HB1 10 mg/kg 60 Male Unknown
2HB2 10 mg/kg 34 Male White
2HB3 10 mg/kg 34 Male Black
2HC1 30 mg/kg 49 Male White
2HC2 30 mg/kg 58 Female Black
2HC3 30 mg/kg 52 Male White
2HD1 30 mg/kg 28 Female Black
2HD2 30 mg/kg 25 Male Multiple
2HD3 30 mg/kg 39 Male Black
2HD4 30 mg/kg 57 Male White/Hispanic
2HD5 30 mg/kg 27 Female White
Study ID 10-1074 dose Age        (years) Gender Race
Years since    
HIV-1 diagnosis
HIV-1     
clade
ART regimen         
at enrollment**
HIV-1-RNA at day 0*** 
(copies/ml)
CD4+ T cell count               
at day 0 (cells/ l)
1HA1 3 mg/kg 47 Male Black 26 ND RPV/TDF/FTC <20D 750
1HA2 3 mg/kg 36 Male Black/Hispanic 3 ND EVG/cobi/TDF/FTC <20D 745
1HA3 3 mg/kg 49 Female White/Hispanic 20 ND EFV/TDF/FTC <20 484
1HB1 10 mg/kg 32 Male Black 15 B - 13,920 449
1HB2 10 mg/kg 26 Male Black 3 B - 6,380 520
1HB3 10 mg/kg 53 Female Black 19 B - 35,810 616
1HC1 30 mg/kg 53 Male Black 21 B - 1,460 289*
1HC2 30 mg/kg 25 Male Black 1 B - 77,610 607
1HC3 30 mg/kg 33 Male Black 6 B - 20,140 411
1HD1 30 mg/kg 25 Male Black 2 B - 41,770 520
1HD2 30 mg/kg 51 Female White 16 B - 840 447
1HD4K 30 mg/kg 46 Male White 6 B - 60,300 330
1HD5K 30 mg/kg 42 Male White 3 B - 7,570 630
1HD6K 30 mg/kg 38 Male White 2 B - 10,100 700
1HD7K 30 mg/kg 53 Male White 7 B - 9,250 860
1HD8K 30 mg/kg 45 Male White 2 B - 11,000 880
1HD9K 30 mg/kg 27 Male White 4 B - 6,960 810
1HD10K 30 mg/kg 44 Male White 11 B - 10,500 760
1HD11K 30 mg/kg 24 Male White 2 B - 63,400 460
* Absolute CD4+ T cell count was 342 cells/ l at screening.
** RPV - rilpivirine, TDF - tenofovir disoproxil, FTC - emtricitabine, EVG - elvitegravir, cobi - cobicistat, EFV - efavirenz.
*** <20D - HIV-1-RNA detected but below limit of quantification (20 copies/ml). <20 - No HIV-1 RNA detected.
ND: Not determined.
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Supplementary Table 2. Safety data*
Adverse Events Reported         AEs




Possibly   
related Mild Moderate Severe
3 mg/kg   
(n=3)
10 mg/kg   
(n=3)
30 mg/kg   
(n=8)
3 mg/kg   
(n=3)
10 mg/kg   
(n=3)
30 mg/kg   
(n=13)
Upper respiratory infection 15 26.32 39.4 - 15 - - 1 1 9 - 1 3
Headache 6 10.53 18.2 5 5 1 - - 2 1 - 1 2
Skin infection                                               
(folliculitis, furunculosis, tinea corporis) 4 7.02 12.1 - 4 - - - - 1 2 - 1
Surgical and medical procedures                              
(mammoplasty, hysterectomy, tooth extraction) 3 5.26 6.1 - 1 1 1 - - - 2 - 1
Arthralgia 2 3.51 6.1 - 2 - - - 1 1 - - -
Dyspepsia 2 3.51 6.1 - 1 1 - 1 - 1 - - -
Gastroenteritis 2 3.51 6.1 - 1 1 - - - - - - 2
Localized musculoskeletal pain 2 3.51 6.1 - 2 - - - - - - 1 1
Rash 2 3.51 6.1 - 1 1 - - - - - - 2
Vomiting / Nausea 2 3.51 6.1 - 2 - - 1 - - - - 1
Abdominal pain 1 1.75 3.0 1 1 - - - - - - 1 -
Diplopia 1 1.75 3.0 - 1 - - - - - 1 - -
Dizziness 1 1.75 3.0 1 1 - - - - - 1 - -
Depressive episode 1 1.75 3.0 - 1 - - - - - - - 1
Dry eyes 1 1.75 3.0 1 1 - - - - - - 1 -
Elevated total bilirubin 1 1.75 3.0 1 1 - - - - - - - 1
Epistaxis 1 1.75 3.0 - 1 - - - - 1 - - -
Head injury due to fall 1 1.75 3.0 - 1 - - - - - - 1 -
Herpes zoster 1 1.75 3.0 - 1 - - - - - - - 1
Increased blood pressure 1 1.75 3.0 - - 1 - - - - 1 - -
Malaise/Fatigue 1 1.75 3.0 1 1 - - - - - - 1 -
Menorrhagia 1 1.75 3.0 - 1 - - - - - 1 - -
Pruritus 1 1.75 3.0 1 1 - - - - - - - 1
Soft tissue hematoma 1 1.75 3.0 - 1 - - - - - - - 1
Toothache 1 1.75 3.0 - 1 - - - - - 1 - -
Traumatic ear injury 1 1.75 3.0 - 1 - - - - - - - 1
Urinary tract infection 1 1.75 3.0 - 1 - - - - 1 - - -
 Uninfected HIV-1-infected
no. of adverse events
* Adverse events reported during 24 weeks of follow-up after 10-1074 infusion by 14/14 HIV-1-negative and 16/19 HIV-1-infected individuals (1HA1-1HD8K), and during 12 (1HD11K) and 20 (1HD9K, 
1HD10K) weeks of follow up by the remaining 3 HIV-1 infected individuals. 
no. of adverse events
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Supplementary Table 3. Clinical parameters and 10-1074 serum activity
1HA1 CD4+   T cells VL VL
Control 
(MuLV) 1HA2
CD4+   
T cells VL VL
Control 
(MuLV) 1HA3
CD4+   
T cells VL VL
Control 
(MuLV)
Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50
Screen 764 <20 - - - - Screen 618 <20D - - - - Screen 702 <20 - - - -
Pre - <20D - - - - Pre - <20D - - - - Pre - <20 - - - -
Day 0 Base 750 <20D - <20 <0.34 <20 Day 0 Base 745 <20D - <20 <0.34 <20 Day 0 Base 484 <20 - <20 <0.34 <20
Day 0 End - - - 3,419 44.4 <20 Day 0 End - - - 4,329 56.3 <20 Day 0 End - - - 4,826 62.7 <20
Day 1 - <20D - 2,433 31.6 <20 Day 1 - <20D - 3,298 42.9 <20 Day 1 - <20 - 4,475 58.2 <20
Day 2 - <20 - 2,346 30.5 <20 Day 2 - <20D - 2,391 31.1 <20 Day 2 - <20D - 2,039 26.5 <20
Day 4 - <20D - NA NA 22 Day 4 - <20 - 1,632 21.2 <20 Day 4 - <20D - 1,451 18.9 <20
Day 7 773 30 - 1,494 19.4 <20 Day 7 (+1) 1,021 <20D - 919 11.9 <20 Day 7 551 <20 - 1,193 15.5 <20
Day 14 (-1) 837 <20 - 510 6.6 <20 Day 14 (+1) 865 <20 - 655 8.5 <20 Day 14 305 <20 - 484 6.3 <20
Day 21 - <20 - 290 3.8 <20 Day 21 (+1) - <20D - 370 4.8 <20 Day 21 - <20D - 652 8.5 <20
Day 28 676 <20D - 217 2.8 <20 Day 28 (+1) 968 <20D - 267 3.5 <20 Day 28 (-3) 419 <20 - 314 4.1 <20
Day 42 - <20 - 97 1.3 <20 Day 42 (+1) - <20 - 114 1.5 <20 Day 42 - <20 - 149 1.9 <20
Day 56 708 <20D - 60 0.8 <20 Day 56 (+1) 848 <20D - 73 0.9 <20 Day 56 403 <20 - 123 1.6 <20
Day 84 - <20D - 26 0.3 <20 Day 84 (+1) - <20 - 39 0.5 <20 Day 84 - <20 - 48 0.6 <20
Day 112 802 <20 - NA NA 21 Day 112 (-6) 836 <20 - 24 0.3 <20 Day 112 574 <20D - NA NA 20
Day 140 (+1) - <20 - NA NA 25 Day 140 (-6) - <20 - <20 <0.26 <20 Day 140 (+8) - <20D - <20 <0.26 <20
Day 168 742 <20D - 23 0.3 <20 Day 168 (-1) 1,113 <20 - <20 <0.26 <20 Day 168 (+3) 595 20 - <20 <0.26 <20
1HB1 CD4+   T cells VL VL
Control 
(MuLV) 1HB2
CD4+   
T cells VL VL
Control 
(MuLV) 1HB3
CD4+   
T cells VL VL
Control 
(MuLV)
Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50
Screen 451 29,180 - - - - Screen 572 8,930 - - - - Screen 487 1,330 - - - -
Pre - 21,160 - - - - Pre - 7,310 - - - - Pre - 8,070 - - - -
Day 0 Base 449 13,920 - <20 <0.26 <20 Day 0 Base 520 6,380 - <20 <0.26 <20 Day 0 Base 616 35,810 - <20 <0.26 59
Day 0 End - - - 7,786 167.4 <20 Day 0 End - - - 12,586 270.6 <20 Day 0 End - - - 2,794 60.1 <20
Day 1 - 12,790 0.0 5,827 125.3 <20 Day 1 - 5,780 0.0 8,300 178.5 <20 Day 1 - 30,780 -0.1 7,456 160.3 <20
Day 2 - 9,450 -0.2 5,620 120.8 <20 Day 2 - 6,320 0.0 6,499 139.7 <20 Day 2 - 11,880 -0.5 6,050 130.1 <20
Day 4 - 2,610 -0.7 2,964 63.7 <20 Day 4 (-1) - 2,090 -0.5 4,894 105.2 <20 Day 4 (-1) - 15,660 -0.4 4,756 102.3 <20
Day 7 (+2) 571 380 -1.6 2,108 45.3 <20 Day 7 (+2) 583 190 -1.5 2,217 47.7 <20 Day 7 553 2,990 -1.1 2,680 57.6 <20
Day 14 (+1) 518 1,840 -0.9 866 18.6 <20 Day 14 (+1) 509 360 -1.2 2,067 44.4 <20 Day 14 542 11,590 -0.5 1,655 35.6 <20
Day 21 - 7,540 -0.3 532 11.4 <20 Day 21 (-1) - 950 -0.8 792 17.0 <20 Day 21 - 28,150 -0.1 990 21.3 <20
Day 28 475 14,660 0.0 318 6.8 <20 Day 28 (+1) 749 8,110 0.1 348 7.5 <20 Day 28 629 17,380 -0.3 523 11.2 <20
Day 42 (+1) - 18,980 0.1 129 2.8 <20 Day 42 (+1) - 3,050 -0.3 135 2.9 <20 Day 42 (-1) - 23,510 -0.2 248 5.3 <20
Day 56 474 19,190 0.1 85 1.8 <20 Day 56 (+1) 458 70 - 143 1.9 <20 Day 56 513 36,580 0.0 155 3.3 <20
Day 84 (+2) - 11,930 -0.1 <20 <0.43 <20 Day 84 - 50 - - - <20 Day 84 (+2) - 36,990 0.0 <20 <0.43 <20
Day 112 475 13,000 0.0 <20 <0.43 <20 Day 112 (-1) 785 <20D - <20 <0.26 <20 Day 112 (+7) 500 37,640 0.0 <20 <0.43 ND
Day 140 (+3) - 27,320 0.3 <20 <0.43 <20 Day 140 (+3) - <20 - NA NA 28 Day 140 (+9) - 140 - <20 <0.26 <20
Day 168 (+1) 501 16,600 0.1 <20 <0.43 <20 Day 168 (+7) 754 <20 - NA NA 21 Day 168 656 1,110 - <20 <0.26 <20
1HC1 CD4+   T cells VL VL
Control 
(MuLV) 1HC2
CD4+   
T cells VL VL
Control 
(MuLV) 1HC3
CD4+   
T cells VL VL
Control 
(MuLV)
Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50
Screen 342 3,300 - - - - Screen 517 45,320 - - - - Screen 322 13,480 - - - -
Pre - 2,260 - - - - Pre - 18,490 - - - - Pre - 11,780 - - - -
Day 0 Base 289 1,460 - <20 <0.26 <20 Day 0 Base 607 77,610 - <20 <0.26 <20 Day 0 Base 411 20,140 - <20 <0.26 <20
Day 0 End - - - 27,478 590.8 <20 Day 0 End - - - 49,761 1,069.9 <20 Day 0 End - - - 20,132 926.1 <20
Day 1 - 2,300 0.2 23,756 510.8 <20 Day 1 - 43,400 -0.3 20,719 445.5 <20 Day 1 - 9,090 -0.3 20,339 935.6 <20
Day 2 - 1,450 0.0 17,918 385.2 <20 Day 2 - 75,000 0.0 17,233 370.5 <20 Day 2 - 6,000 -0.5 11,238 516.9 <20
Day 4 - 400 -0.6 10,528 226.4 <20 Day 4 (-1) - 29,990 -0.4 16,211 348.5 <20 Day 4 - 1,430 -1.1 8,947 411.6 <20
Day 7 338 140 -1.0 8,763 188.4 <20 Day 7 708 1,500 -1.7 13,913 299.1 <20 Day 7 432 520 -1.6 8,171 375.9 <20
Day 14 354 180 -0.9 5,450 117.2 <20 Day 14 683 2,000 -1.6 6,039 129.8 <20 Day 14 426 10,670 -0.3 2,751 126.5 <20
Day 21 - 390 -0.6 2,419 52.0 <20 Day 21 - 13,430 -0.8 3,619 77.8 <20 Day 21 - 11,190 -0.3 1,864 85.7 <20
Day 28 300 1,840 0.1 1,376 29.6 <20 Day 28 583 49,840 -0.2 2,166 46.6 <20 Day 28 388 20,800 0.0 1,102 50.7 <20
Day 42 - 1,370 0.0 460 9.9 <20 Day 42 - 30,480 -0.4 1,166 25.1 <20 Day 42 - 11,200 -0.3 379 17.4 <20
Day 56 330 730 -0.3 215 4.6 <20 Day 56 (-4) 502 40 - 358 4.7 <20 Day 56 364 17,590 -0.1 211 9.7 <20
Day 84 - 1,850 0.1 47 1.0 <20 Day 84 - <20 - 55 0.7 <20 Day 84 (-5) - 13,480 -0.2 49 2.3 <20
Day 112 (+2) 354 5,730 0.6 <20 <0.43 <20 Day 112 662 <20D - <20 <0.26 <20 Day 112 (+1) 478 <20 - <20 <0.26 <20
Day 140 (-4) - 3,080 0.3 <20 <0.43 <20 Day 140 (+3) - <20 - <20 <0.26 <20 Day 140 (+1) - <20 - <20 <0.26 <20
Day 168 289 1,460 0.0 <20 <0.43 <20 Day 168 (-1) 1,019 <20D - <20 <0.26 <20 Day 168 467 <20 - <20 <0.26 <20
1HD1 CD4+   T cells VL VL
Control 
(MuLV) 1HD2
CD4+   
T cells VL VL
Control 
(MuLV) 1HD4K
CD4+   
T cells VL VL
Control 
(MuLV)
Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50
Screen 510 64,130 - - - - Screen 455 830 - - - - Screen 380 26,000 - - - -
Pre - 37,350 - - - - Pre - 2,940 - - - - Pre - 53,300 - - - -
Day 0 Base 520 41,770 - <20 <0.26 <20 Day 0 Base 447 840 - <20 <0.26 <20 Day 0 Base 330 60,300 - <20 <0.26 -
Day 0 End - - - 57,033 1,226.2 <20 Day 0 End - - - 103,523 2,225.7 <20 Day 0 End - - - 36,456 947.9 <20
Day 1 - 34,950 -0.1 36,270 779.8 <20 Day 1 - 1,270 0.2 62,389 1,341.4 <20 Day 1 - 34,000 -0.2 30,175 784.6 <20
Day 2 - 7,960 -0.7 34,333 738.2 <20 Day 2 - 610 -0.1 55,847 1,200.7 <20 Day 2 - 34,000 -0.2 20,483 532.6 <20
Day 4 - 3,170 -1.1 35,038 753.3 <20 Day 4 (+1) - 360 -0.4 48,758 1,048.3 <20 Day 4 (-1) - 18,400 -0.5 19,245 500.4 <20
Day 7 636 2,900 -1.2 18,120 389.6 <20 Day 7 449 470 -0.3 16,829 361.8 <20 Day 7 530 5,140 -1.1 16,631 432.4 <20
Day 14 492 60,640 0.2 7,316 157.3 <20 Day 14 (-3) 399 330 -0.4 11,323 243.4 <20 Day 14 420 8,670 -0.8 4,716 122.6 <20
Day 21 - 58,960 0.1 3,374 72.5 <20 Day 21 (+4) - 590 -0.2 1,965 42.2 <20 Day 21 - 6,420 -1.0 3,404 88.5 <20
Day 28 504 26,710 -0.2 2,270 48.8 <20 Day 28 (+5) 404 1,010 0.1 767 16.5 <20 Day 28 400 60,000 0.0 2,141 55.7 <20
Day 42 (-5) - 53,300 0.1 995 21.4 <20 Day 42 (-3) - 660 -0.1 579 12.4 <20 Day 42 - 44,500 -0.1 1,156 30.1 <20
Day 56 (-7) 546 32,940 -0.1 517 11.1 <20 Day 56 (+6) 479 350 -0.4 71 1.5 <20 Day 56 480 61,700 0.0 740 19.2 <20
Day 84 - 15,640 -0.4 30 0.6 <20 Day 84 (-4) - 270 -0.5 <20 <0.43 <20 Day 84 410 47,300 -0.1 157 3.6 <20
Day 112 497 24,020 -0.2 <20 <0.43 <20 Day 112 (-7) 352 150 -0.7 <20 <0.43 <20 Day 112 590 210 - 126 1.8 <20
Day 140 (+3) - 29,700 -0.1 <20 <0.43 <20 Day 140 (-7) - 370 -0.4 <20 <0.43 <20 Day 140 (+7) 750 <20D - 28 0.4 <20
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Supplementary Table 3. Clinical parameters and 10-1074 serum activity - continued
<20D:    HIV-1 RNA detected below limit of quantification (20 copies/ml).
NA:    Not assessed because of unspecific serum activity against MuLV-pseudotyped virus.
Grey shading:   Subject on antiretroviral therapy.
Blue shading: Use of ART-resistant pseudovirus backbone.  
1HD5K CD4+   T cells VL VL
Control 
(MuLV) 1HD6K
CD4+   
T cells VL VL
Control 
(MuLV) 1HD7K
CD4+   
T cells VL VL
Control 
(MuLV)
Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50
Screen 540 97,700 - - - - Screen 590 8,690 - - - - Screen 830 5,950 - - - -
Pre - 9,720 - - - - Pre - 14,100 - - - - Pre - 5,350 - - - -
Day 0 Base 630 7,570 - <20 <0.26 - Day 0 Base 700 10,100 - <20 <0.26 - Day 0 Base 860 9,250 - <20 <0.26 -
Day 0 End - - - 30,595 795.5 <20 Day 0 End - - - 45,073 1171.9 <20 Day 0 End - - - 24,017 624.4 <20
Day 1 - 7,300 0.0 20,152 524.0 <20 Day 1 - 9,910 0.0 29,675 771.6 <20 Day 1 - 9,330 0.0 28,574 742.9 <20
Day 2 - 4,980 -0.2 16,813 437.1 <20 Day 2 - 8,190 -0.1 21,180 550.7 <20 Day 2 - 8,430 0.0 16,122 419.2 <20
Day 4 - 1,400 -0.7 20,303 527.9 <20 Day 4 - 1,310 -0.9 19,734 513.1 <20 Day 4 (-1) - 5,820 -0.2 10,544 274.1 <20
Day 7 550 367 -1.3 12,165 316.3 <20 Day 7 (+2) 840 119 -1.9 11,431 297.2 <20 Day 7 990 1,170 -0.9 9,166 238.3 <20
Day 14 (+1) 680 404 -1.3 7,971 207.2 <20 Day 14 (+1) 620 131 -1.9 6,497 168.9 <20 Day 14 880 1,250 -0.9 2,553 66.4 <20
Day 21 (-3) - 661 -1.1 4,779 124.3 <20 Day 21 (+4) - 87 -2.1 2,427 63.1 <20 Day 21 - 1,820 -0.7 1,230 32.0 <20
Day 28 630 2,960 -0.4 3,084 80.2 <20 Day 28 (+4) 890 314 -1.5 2,782 72.3 <20 Day 28 960 5,990 -0.2 748 19.4 <20
Day 42 - 39,900 0.7 2,034 52.9 <20 Day 42 - 160 -1.8 952 24.8 <20 Day 42 - 7,000 -0.1 282 7.3 <20
Day 56 560 114,000 1.2 1,523 39.6 <20 Day 56 (+2) 1,040 992 -1.0 249 6.5 <20 Day 56 750 6,140 -0.2 85 2.2 <20
Day 84 690 <20D - NA NA 37 Day 84 - 10,100 0.0 36 0.6 <20 Day 84 - 9,880 0.0 <20 <0.36 <20
Day 112 680 <20 - NA NA 41 Day 112 1,100 5,900 -0.2 <20 <0.36 <20 Day 112 840 11,100 0.1 <20 <0.36 <20
Day 140 600 <20 - NA NA 26 Day 140 (+9) - 11,600 0.1 <20 <0.36 <20 Day 140 - 10,900 0.1 <20 <0.36 <20
Day 168 600 <20 - 96 1.4 <20 Day 168 660 3,240 -0.5 <20 <0.54 <20 Day 168 (+1) 910 10,600 0.1 <20 <0.54 <20
1HD8K CD4+   T cells VL VL
Control 
(MuLV) 1HD9K
CD4+   
T cells VL VL
Control 
(MuLV) 1HD10K
CD4+   
T cells VL VL
Control 
(MuLV)
Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50 Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50
Screen 780 9,600 - - - - Screen 830 763 - - - - Screen 630 7,100 - - - -
Pre - 10,800 - - - - Pre - 5,770 - - - - Pre - 7,390 - - - -
Day 0 Base 880 11,000 - <20 <0.26 - Day 0 Base 810 6,960 - <20 <0.64 <20 Day 0 Base 760 10,500 - <20 <0.64 <20
Day 0 End - - - 34,336 892.7 <20 Day 0 End - - - 17,890 1395.4 <20 Day 0 End - - - 18,618 1452.2 <20
Day 1 - 6,690 -0.2 30,519 793.5 <20 Day 1 - 6,510 0.0 10,705 835.0 <20 Day 1 - 12,100 0.1 8,339 650.4 <20
Day 2 - 7,350 -0.2 24,208 629.4 <20 Day 2 - 6,770 0.0 8,450 659.1 <20 Day 2 - 8,680 -0.1 9,085 708.6 <20
Day 4 - 1,370 -0.9 16,044 417.1 <20 Day 4 - 5,830 -0.1 6,183 482.3 <20 Day 4 - 1,030 -1.0 4,719 368.1 <20
Day 7 1,030 173 -1.8 9,340 242.8 <20 Day 7 660 8,120 0.1 4,514 352.1 <20 Day 7 650 496 -1.3 5,725 446.6 <20
Day 14 (-3) 760 103 -2.0 7,825 203.5 <20 Day 14 560 8,310 0.1 2,432 189.7 <20 Day 14 750 205 -1.7 1,718 134.0 <20
Day 21 (+4) - 817 -1.1 5,950 154.7 <20 Day 21 - 21,400 0.5 2,326 181.4 <20 Day 21 - 124 -1.9 880 68.6 <20
Day 28 830 1,000 -1.0 3,976 103.4 <20 Day 28 640 18,600 0.4 774 60.4 <20 Day 28 800 503 -1.3 670 52.3 <20
Day 42 - 7,710 -0.2 1,933 50.3 <20 Day 42 - 12,800 0.3 404 31.5 <20 Day 42 - 1,330 -0.9 300 23.4 <20
Day 56 910 <20 - 2,576 36.1 <20 Day 56 (+4) 730 16,800 0.4 138 10.8 <20 Day 56 750 2,670 -0.6 105 8.2 <20
Day 84 (+7) 930 <20 - NA NA 92 Day 84 (-2) - 9,910 0.2 48 0.9 <20 Day 84 - 12,900 0.1 21 0.4 <20
Day 112 - <20 - 444 6.2 <20 Day 112 (-7) 660 3,840 -0.3 <20 <0.54 <20 Day 112 710 2,440 -0.6 <20 <0.54 <20
Day 140 (-5) - <20 - 296 4.1 <20 Day 140 (-3) - 18,700 0.4 <20 <0.54 <20 Day 140 - 34,600 0.5 <20 <0.54 <20
Day 168 900 <20 - 95 1.4 <20 Day 168 - - - - - - Day 168 - - - - - -
1HD11K CD4+   T cells VL VL
Control 
(MuLV)
Timepoint cells/ l cp/ml log10 ID50 µg/ml ID50
Screen 580 88,500 - - - -
Pre - 99,800 - - - -
Day 0 Base 460 63,400 - <20 <0.80 <20
Day 0 End - - - 26,198 471.6 <20
Day 1 - 14,500 -0.6 30,170 543.1 <20
Day 2 - 22,400 -0.5 25,584 460.5 <20
Day 4 (-1) - 6,170 -1.0 22,916 412.5 <20
Day 7 500 757 -1.9 9,839 177.1 <20
Day 14 470 10,700 -0.8 4,804 86.5 <20
Day 21 - 79,300 0.1 3,530 63.5 <20
Day 28 470 50,500 -0.1 2,359 42.5 <20
Day 42 - 83,400 0.1 1,057 28.5 <20
Day 56 440 97,000 0.2 354 9.6 <20
Day 84 - 224,000 0.5 - - -
Day 112 - - - - - -
Day 140 - - - - - -
Day 168 - - - - - -
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Supplementary Table 3. Clinical parameters and 10-1074 serum activity - continued
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Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50
Screen - - - Screen - - - Screen - - -
Pre - - - Pre - - - Pre - - -
Day 0 Base <20 <1.16 <20 Day 0 Base <20 <1.59 <20 Day 0 Base <20 <1.59 <20
Day 0 End 1,112 64.5 <20 Day 0 End 1,637 130.1 <20 Day 0 End 1,005 79.9 <20
Day 1 915 53.1 <20 Day 1 982 78.1 <20 Day 1 1,013 80.5 <20
Day 2 615 35.7 <20 Day 2 877 69.7 <20 Day 2 734 58.4 <20
Day 4 (+2) 567 32.9 <20 Day 4 678 53.9 <20 Day 4 (+1) 395 31.4 <20
Day 7 595 34.5 <20 Day 7 447 35.5 <20 Day 7 355 28.2 <20
Day 14 259 20.6 <20 Day 14 367 29.2 <20 Day 14 289 23.0 <20
Day 21 200 15.9 <20 Day 21 244 19.4 <20 Day 21 264 21.0 <20
Day 28 173 13.8 <20 Day 28 168 13.4 <20 Day 28 (+1) 154 12.2 <20
Day 42 112 8.9 <20 Day 42 86 6.8 <20 Day 42 121 9.6 <20
Day 56 104 8.3 <20 Day 56 68 5.4 <20 Day 56 97 7.7 <20
Day 84 46 3.7 <20 Day 84 (+2) <20 <1.59 <20 Day 84 (-1) 25 2.0 <20
Day 112 (+7) 21 1.7 <20 Day 112 (+2) <20 <1.59 <20 Day 112 (+1) <20 <1.59 <20
Day 140 (+2) 22 1.7 <20 Day 140 <20 <1.59 <20 Day 140 (-5) <20 <1.59 <20
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Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50
Screen - - - Screen - - - Screen - - -
Pre - - - Pre - - - Pre - - -
Day 0 Base <20 <1.16 <20 Day 0 Base <20 <1.59 <20 Day 0 Base <20 <1.59 <20
Day 0 End 6,178 358.3 <20 Day 0 End 5,092 404.8 <20 Day 0 End 4,163 331.0 <20
Day 1 4,168 241.7 <20 Day 1 2,405 191.2 <20 Day 1 2,965 235.7 <20
Day 2 2,405 139.5 <20 Day 2 2,218 176.3 <20 Day 2 2,594 206.2 <20
Day 4 1,849 107.2 <20 Day 4 (-1) 1,966 156.3 <20 Day 4 (-1) 2,025 161.0 <20
Day 7 1,449 84.0 <20 Day 7 1,665 132.4 <20 Day 7 1,224 97.3 <20
Day 14 1,306 103.8 <20 Day 14 1,555 123.6 <20 Day 14 859 68.3 <20
Day 21 755 60.0 <20 Day 21 850 67.6 <20 Day 21 637 50.6 <20
Day 28 508 40.4 <20 Day 28 550 43.7 <20 Day 28 607 48.3 <20
Day 42 335 26.6 <20 Day 42 (+1) 468 37.2 <20 Day 42 (-1) 283 22.5 <20
Day 56 (+3) 168 13.4 <20 Day 56 (+3) 306 24.3 <20 Day 56 (+1) 178 14.2 <20
Day 84 (+3) 109 8.7 <20 Day 84 (+3) 149 11.8 <20 Day 84 (-1) 103 8.2 <20
Day 112 24 1.9 <20 Day 112 (+3) 98 7.8 <20 Day 112 46 3.7 <20
Day 140 (-3) 21 1.7 <20 Day 140 79 6.3 <20 Day 140 (-7) 23 1.8 <20
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Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50
Screen - - - Screen - - - Screen - - - Screen - - -
Pre - - - Pre - - - Pre - - - Pre - - -
Day 0 Base <20 <1.16 <20 Day 0 Base <20 <1.59 <20 Day 0 Base <20 <1.59 <20 Day 0 Base <20 <1.16 <20
Day 0 End 24,299 1,409.3 <20 Day 0 End 22,159 1,761.6 <20 Day 0 End 25,035 1,990.3 <20 Day 0 End 22,728 1,318.2 <20
Day 1 13,753 797.7 <20 Day 1 13,342 1,060.7 <20 Day 1 17,749 1,411.0 <20 Day 1 12,917 749.2 <20
Day 2 (+1) 13,021 755.2 <20 Day 2 11,342 901.7 <20 Day 2 15,288 1,215.4 <20 Day 2 8,687 503.8 <20
Day 4 6,905 400.5 <20 Day 4 9,697 770.9 <20 Day 4 14,159 1,125.6 <20 Day 4 9,290 538.8 <20
Day 7 (+1) 6,083 352.8 <20 Day 7 6,467 514.1 <20 Day 7 4,524 359.7 <20 Day 7 6,807 394.8 <20
Day 14 4,575 363.7 <20 Day 14 3,521 279.9 <20 Day 14 3,120 248.0 <20 Day 14 (+1) 5,048 401.3 <20
Day 21 2,825 224.6 <20 Day 21 2,715 215.8 <20 Day 21 1,974 156.9 <20 Day 21 1,929 153.4 <20
Day 28 (+6) 1,271 101.0 <20 Day 28 (+2) 2,390 190.0 <20 Day 28 (+2) 1,224 97.3 <20 Day 28 (+1) 1,362 108.3 <20
Day 42 (+2) 786 62.5 <20 Day 42 (+1) 2,907 231.1 <20 Day 42 (-4) 1,462 116.2 <20 Day 42 (+4) 827 65.7 <20
Day 56 (+2) 407 32.4 <20 Day 56 (+9) 976 77.6 <20 Day 56 (+1) 439 34.9 <20 Day 56 442 35.1 <20
Day 84 (+2) 130 10.3 <20 Day 84 (+2) 512 40.7 <20 Day 84 (+2) 185 14.7 <20 Day 84 (+3) 333 26.5 <20
Day 112 54 4.3 <20 Day 112 (+4) 221 17.6 <20 Day 112 (+2) 65 5.2 <20 Day 112 (+1) 112 8.9 <20
Day 140 21 1.7 <20 Day 140 (+4) 155 12.3 <20 Day 140 (-3) 46 3.7 <20 Day 140 (+1) 56 4.5 <20
Day 168 <20 <1.59 <20 Day 168 (+8) 72 5.7 <20 Day 168 (+1) <20 <1.59 <20 Day 168 (+4) <20 <1.26 <20







Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50 Timepoint ID50 µg/ml ID50
Screen - - - Screen - - - Screen - - - Screen - - -
Pre - - - Pre - - - Pre - - - Pre - - -
Day 0 Base <20 <1.59 <20 Day 0 Base <20 <1.59 <20 Day 0 Base <20 <1.59 - Day 0 Base <20 <1.59 <20
Day 0 End 19,872 1,579.8 <20 Day 0 End 17,652 1,403.3 <20 Day 0 End 12,156 966.4 <20 Day 0 End 8,290 659.1 <20
Day 1 23,001 1,828.6 <20 Day 1 12,852 1,021.7 <20 Day 1 8,507 676.3 <20 Day 1 5,498 437.1 <20
Day 2 8,687 690.6 <20 Day 2 13,275 1,055.4 <20 Day 2 7,543 599.7 <20 Day 2 5,823 462.9 <20
Day 4 7,289 579.5 <20 Day 4 4,244 337.4 <20 Day 4 (-1) 9,117 724.8 <20 Day 4 4,385 348.6 <20
Day 7 (+1) 5,773 459.0 <20 Day 7 4,176 332.0 <20 Day 7 (+1) 4,567 363.1 <20 Day 7 3,040 241.7 <20
Day 14 4,116 327.2 <20 Day 14 2,488 197.8 <20 Day 14 (+1) 2,235 177.7 <20 Day 14 1,916 152.3 <20
Day 21 (+1) 3,205 254.8 <20 Day 21 (+1) 1,399 111.2 <20 Day 21 (+1) 1,787 142.1 <20 Day 21 (+1) 1,597 127.0 <20
Day 28 1,589 126.3 <20 Day 28 (+1) 1,232 97.9 <20 Day 28 (+1) 1,226 97.5 <20 Day 28 (+1) 1,319 104.9 <20
Day 42 990 78.7 <20 Day 42 (+3) 377 30.0 <20 Day 42 (+1) 1,016 80.8 <20 Day 42 (+1) 835 66.4 <20
Day 56 743 59.1 <20 Day 56 249 19.8 <20 Day 56 (+14) 341 27.1 <20 Day 56 (+2) 464 36.9 <20
Day 84 259 20.6 <20 Day 84 (+1) 72 5.7 <20 Day 84 (+1) 227 18.0 <20 Day 84 279 22.2 <20
Day 112 141 11.2 <20 Day 112 (+1) <20 <1.59 <20 Day 112 (+2) 135 10.7 <20 Day 112 (+2) 128 10.2 <20
Day 140 (-4) 68 5.4 <20 Day 140 (+3) <20 <1.59 <20 Day 140 73 5.8 <20 Day 140 (+4) 87 6.9 <20
Day 168 47 4.8 <20 Day 168 (+3) <20 <2.06 <20 Day 168 (+1) 56 5.8 <20 Day 168 (+14) - - -
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Supplementary Table 4. Pharmacokinetics of 10-1074 























2HA1 Negative 3 mg/kg TZM.bl (Du422.1) 64.5 0.96 34.0 14 142 1,338.0 142 1.75 4.8
2HA2 Negative 3 mg/kg TZM.bl (Du422.1) 130.1 0.97 16.8 7 56 1,281.1 56 5.41 8.7
2HA3 Negative 3 mg/kg TZM.bl (Du422.1) 80.5 0.97 20.8 5 83 1,270.0 83 1.99 5.6
1HA1 Positive 3 mg/kg TZM.bl (3103.v3.c10) 44.4 0.99 17.2 21 84 418.8 168 0.30 0.1
1HA2 Positive 3 mg/kg TZM.bl (3103.v3.c10) 56.3 0.92 19.7 15 106 436.2 106 0.30 1.5
1HA3 Positive 3 mg/kg TZM.bl (3103.v3.c10) 62.7 0.92 19.1 14 84 471.1 84 0.60 3.3
2HB1 Negative 10 mg/kg TZM.bl (Du422.1) 358.3 0.97 21.0 7 137 3,924.7 137 1.67 1.0
2HB2 Negative 10 mg/kg TZM.bl (Du422.1) 404.8 0.97 36.8 21 168 5,543.0 168 3.82 3.2
2HB3 Negative 10 mg/kg TZM.bl (Du422.1) 331.0 0.99 22.8 7 133 3,862.5 133 1.83 1.5
1HB1 Positive 10 mg/kg TZM.bl (3103.v3.c10) 167.4 0.97 12.1 15 56 1,193.1 56 1.80 2.3
1HB2 Positive 10 mg/kg TZM.bl (3103.v3.c10) 270.6 0.93 9.5 9 57 1,619.0 57 1.90 1.2
1HB3 Positive 10 mg/kg TZM.bl (3103.v3.c10) 160.3 0.96 11.5 7 56 1,535.7 56 3.30 2.8
2HC1 Negative 30 mg/kg TZM.bl (Du422.1) 1,409.3 0.99 16.4 8 140 13,400.1 140 1.67 0.2
2HC2 Negative 30 mg/kg TZM.bl (Du422.1) 1,761.6 0.97 27.8 14 176 21,427.5 176 5.72 1.0
2HC3 Negative 30 mg/kg TZM.bl (Du422.1) 1,990.3 0.98 19.3 7 137 15,646.8 137 3.66 0.5
2HD1 Negative 30 mg/kg TZM.bl (Du422.1) 1,318.2 0.97 24.3 21 141 13,689.5 141 4.45 1.1
2HD2 Negative 30 mg/kg TZM.bl (Du422.1) 1,828.6 0.96 27.8 28 168 16,480.4 168 4.84 0.8
2HD3 Negative 30 mg/kg TZM.bl (Du422.1) 1,403.3 0.98 13.8 14 85 10,173.9 85 5.72 1.0
2HD4 Negative 30 mg/kg TZM.bl (Du422.1) 966.4 0.97 26.5 29 140 12,585.5 169 5.80 0.7
2HD5 Negative 30 mg/kg TZM.bl (Du422.1) 659.1 0.98 27.9 14 144 9,679.9 144 6.92 2.3
1HC1 Positive 30 mg/kg TZM.bl (3103.v3.c10) 590.8 0.99 11.2 21 84 4,618.8 84 1.00 0.3
1HC2 Positive 30 mg/kg TZM.bl (3103.v3.c10) 1,069.9 0.98 8.9 7 84 6,201.0 84 0.70 0.1
1HC3 Positive 30 mg/kg TZM.bl (3103.v3.c10) 935.6 0.99 11.2 14 79 7,526.8 79 2.30 0.5
1HD1 Positive 30 mg/kg TZM.bl (3103.v3.c10) 1,226.2 1.00 8.9 14 84 8,785.8 84 0.60 0.1
1HD2 Positive 30 mg/kg TZM.bl (3103.v3.c10) 2,225.7 0.99 6.9 7 62 11,457.5 62 1.50 0.1
1HD4K Positive 30 mg/kg TZM.bl (3103.v3.c10) 947.9 0.99 16.1 14 147 8,431.3 147 0.40 0.1
1HD5K Positive 30 mg/kg TZM.bl (3103.v3.c10) 795.5 0.97 21.8 7 168 10,866.9 168 1.40 0.4
1HD6K Positive 30 mg/kg TZM.bl (3103.v3.c10) 1,171.9 0.99 8.6 9 84 8,543.5 84 0.60 0.1
1HD7K Positive 30 mg/kg TZM.bl (3103.v3.c10) 742.9 1.00 8.8 14 56 4,462.4 56 2.20 0.6
1HD8K Positive 30 mg/kg TZM.bl (3103.v3.c10) 892.7 0.99 21.8 7 168 10,441.9 168 1.40 0.4
1HD9K Positive 30 mg/kg TZM.bl (3103.v3.c10) 1,395.4 0.97 9.1 7 82 9,414.1 82 0.90 0.2
1HD10K Positive 30 mg/kg TZM.bl (3103.v3.c10) 1,452.2 0.97 8.7 14 84 8,031.9 84 0.40 0.1
1HD11K Positive 30 mg/kg TZM.bl (3103.v3.c10) 543.1 0.96 12.8 7 56 5,366.5 56 9.60 3.6
a      Pharmacokinetics by study subject
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Mean SD Range Mean SD Range
3 mg/kg Negative 3 91.7 34.2 64.5 - 130.1 23.9 9.0 16.8 - 34.0
3 mg/kg Positive 3 54.5 9.3 44.4 - 62.7 18.7 1.3 17.2 - 19.7
10 mg/kg Negative 3 364.7 37.3 331 - 404.8 26.9 8.6 21.0 - 36.8
10 mg/kg Positive 3 199.4 61.7 160.3 - 270.6 11.0 1.4 9.5 - 12.1
30 mg/kg Negative 8 1,417 447.9 659.1 - 1,990 23.0 5.7 13.8 - 27.9
30 mg/kg Positive 13 1,076 445.0 543.1 - 2,226 11.9 5.0 6.9 - 21.8
All Negative 14 24.0 6.6 13.8 - 36.8
All Positive 19 12.8 4.9 6.9 - 21.8
Cmax ( g/ml) t1/2 (days)
b      Pharmacokinetics by study group
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Supplementary Table 5. Single Genome Sequence analysis (positions 325 and 332-334)*
*Sequences containing premature stopcodons or large internal deletions that would compromise Env functionality 
 were excluded from this and all other downstream analyses.
# (27) site mt # (nd) site mt # (31) site mt # (31) site mt # (27) site mt # (16) site mt # (27) site mt # (nd) site mt
27 DNIS wt 10 S334 N 18 S334 N 27 DNIS wt 9 DNIS wt 12 S334 N
6 S334 R 7 S334 R 2 N332 S 8 N332 S
5 N332 I 4 N332 S 2 N332 I 5 S334 R
3 N332 T 1 N332 del 1 N332 K 1 S334 G
2 N332 H 1 S334 D 1 S334 N 1 N332 I




# (29) site mt # (16) site mt # (19/28) site mt # (22) site mt # (19) site mt # (nd) site mt # (37) site mt # (28) site mt
15 NNIS wt 7 S334 N 6 / 13 S334 N 5 S334 N 14 DNLS wt 12 DNLS wt 17 DNLS wt
14 DNIS wt 6 NNIS wt 2 / 5 N332 D 4 N332 I 3 DNIS wt 10 N332 T 6 DNIS wt
1 DNIS wt 4 / 4 N332 S 3 N332 T 2 N332 T 6 N332 S 5 N332 T
1 D/N325 G 0 / 1 N332 H 2 DNIS wt 5 DNIS wt
1 N332 S 1 / 1 N332 K 2 D/N325 K 2 S334 N
2 / 1 S334 G 2 S334 R 1 N332 K
0 / 1 S334 I 2 N332 S 1 D/N325 E
1 / 1 D/N325 G 1 N332 K
0 / 1 D/N325 K 1 NNIS wt
2 / 0 D/N325 E
1 / 0 N332 T
# (31) site mt # (26) site mt # (28) site mt # (nd) site mt # (29) site mt # (30) site mt # (32) site mt # (nd) site mt
31 DNIS wt 26 DNIS wt 17 S334 N 29 DNIS wt 12 S334 N 13 S334 N
6 N332 K 5 S334 R 12 N332 S
3 N332 T 5 N332 S 2 N332 I
1 N332 S 2 N332 K 2 N332 K
1 D/N325 E 2 S334 G 1 N332 D
2 DNIS wt 1 S334 G
1 N332 I 1 S334 R
1 N332 D
# (32) site mt # (19) site mt # (24) site mt # (30) site mt # (14) site mt # (nd) site mt # (nd) site mt # (nd) site mt
32 NNIS wt 7 D/N325 K 15 S334 N 17 NNIS wt 14 N332 T
6 S334 N 2 D/N325 K 12 D/N325 K
3 NNIS wt 2 N332 I 1 S334 N
1 S334 I 2 S334 R
1 S334 R 1 N332 D
1 N332 S 1 N332 S
1 N332 T
# (23) site mt # (20) site mt # (33) site mt # (nd) site mt # (23) site mt # (5) site mt # (19) site mt # (nd) site mt
23 DNIS wt 17 DNIS wt 27 N332 D 23 DNIS wt 5 DNIS wt 7 S334 N
1 N332 D 3 S334 N 5 N332 S
1 N332 K 2 N332 K 3 S334 R
1 S334 N 1 S334 R 2 S334 G
1 N332 K
1 N332 Y
# (32) site mt # (nd) site mt # (4/10) site mt # (24/25) site mt # (36) site mt # (nd) site mt # (34) site mt # (nd) site mt
32 DNIS wt 3 / 1 S334 A 20 / 25 DNIS wt 24 DNIS wt 21 S334 N
1 / 1 DNIS wt 1 / 0 S334 Y 12 NNIS wt 6 S334 R
0 / 5 S334 F 1 / 0 S334 F 2 N332 K
0 / 3 S334 Y 1 / 0 N332 K 2 S334 G
1 / 0 D/N325 E 1 N332 S
1 D/N325 K
1 N332 T
# (30) site mt # (nd) site mt # (nd) site mt # (nd) site mt # (19) site mt # (nd) site mt # (12/20) site mt # (23) site mt
30 D/N325 E 19 DNIS wt 5 / 3 S334 N 19 DNIS wt
4 / 8 DNIS wt 2 N332 T
1 / 0 N332 T 2 D/N325 E
1 / 1 S334 R
1 / 2 N332 D
0 / 5 N332 S
0 / 1 D/N325 E
# (36) site mt # (nd) site mt # (31) site mt # (nd) site mt
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Supplementary Table 6. Pseudovirus neutralization data of subjects’ plasma envelopes
#* SGS Sequence ID TP #* SGS Sequence ID TP
1 1HB1-D0-012016-B4_S3 Day0 0.005 0.024 0.012 0.054 0.166 0.544 0.440 2.270 >50 >50 11 1HB2-D0-102315-C3_S1 Day0 0.014 0.029 0.050 0.136 0.026 0.074 0.172 0.483 >50 >50
2 1HB1-D0-012016-C7_S6 Day0 0.002 0.015 0.038 0.326 0.034 0.171 0.086 0.449 >50 >50 12 1HB2-D0-102315-C7_S2 Day0 0.009 0.026 0.029 0.099 0.020 0.070 0.081 0.363 >50 >50
3 1HB1-D0-012016-F10_S11 Day0 0.008 0.037 0.981 8.898 0.030 0.132 0.095 0.446 >50 >50 13 1HB2-D0-102615-B11_S13 Day0 0.007 0.030 0.032 0.124 0.017 0.064 0.129 0.630 >50 >50
4 1HB1-D0-012216-B2_S21 Day0 0.008 0.033 0.040 0.219 0.020 0.055 0.083 0.303 >50 >50 14 1HB2-D0-102615-C8_S18 Day0 0.012 0.024 0.051 0.172 0.025 0.071 0.214 0.492 >50 >50
5 1HB1-D0-012216-G6_S32 Day0 0.004 0.014 0.004 0.026 0.034 0.141 0.218 1.109 >50 >50 15 1HB2-D0-102615-E9_S22 Day0 0.013 0.026 0.058 0.172 0.028 0.079 0.094 0.344 >50 >50
6 1HB1-W4-012016-D10_S47 Wk4 >50 >50 >50 >50 0.027 0.087 0.102 0.381 >50 >50 16 1HB2-W4-103015-A11_S74 Wk4 >50 >50 >50 >50 0.016 0.060 0.109 0.529 >50 >50
7 1HB1-W4-020416-A6_S52 Wk4 >50 >50 >50 >50 0.014 0.041 0.039 0.192 >50 >50 17 1HB2-W4-103015-C9_S80 Wk4 >50 >50 >50 >50 0.013 0.053 0.051 0.273 >50 >50
8 1HB1-W4-020416-B2_S54 Wk4 >50 >50 >50 >50 0.008 0.034 0.030 0.162 >50 >50 18 1HB2-W4-103015-D11_S85 Wk4 >50 >50 >50 >50 0.013 0.045 0.113 0.592 >50 >50
9 1HB1-W4-020416-D3_S58 Wk4 >50 >50 >50 >50 0.042 0.205 0.061 0.336 >50 >50 19 1HB2-W4-103015-D7_S84 Wk4 >50 >50 >50 >50 0.020 0.061 0.127 0.443 >50 >50
10 1HB1-W4-020416-H6_S65 Wk4 >50 >50 >50 >50 0.039 0.187 0.118 0.460 >50 >50 20 1HB2-W4-103015-F1_S87 Wk4 >50 >50 >50 >50 0.025 0.060 0.098 0.311 >50 >50
21 1HB2-W4-103015-F2_S88 Wk4 >50 >50 >50 >50 0.015 0.056 0.140 0.439 >50 >50
22 1HB3-D0-102315-G10_S34 Day0 0.041 0.115 0.012 0.038 0.117 0.320 0.989 5.104 0.443 1.698
23 1HB3-D0-102915-B2_S49 Day0 0.011 0.048 0.007 0.048 0.032 0.105 0.306 1.034 0.399 4.876 31 1HC1-D0-061516-A1_S68 Day0 0.305 1.104 0.148 0.741 0.179 0.657 0.180 0.891 >50 >50
24 1HB3-D0-102915-B6_S51 Day0 0.032 0.160 0.013 0.092 0.128 0.435 1.514 5.752 0.273 1.294 32 1HC1-D0-061516-B5_S69 Day0 >50 >50 0.512 4.575 0.004 0.017 0.019 0.084 >50 >50
25 1HB3-D0-102915-C7_S56 Day0 0.028 0.098 0.008 0.035 0.099 0.431 1.037 4.862 0.491 2.323 33 1HC1-D0-061516-C4_S70 Day0 0.286 1.371 0.154 1.074 0.160 0.568 0.125 0.667 >50 >50
26 1HB3-W4-102815-F7_S45 Wk4 >50 >50 >50 >50 0.184 0.660 2.235 6.231 0.470 1.828 34 1HC1-D0-061616-G4_S15 Day0 0.337 1.179 0.175 1.163 0.134 0.454 0.092 0.336 >50 >50
27 1HB3-W4-110215-C10_S52e Wk4 >50 >50 >50 >50 0.159 0.417 1.284 4.568 0.382 1.314 35 1HC1-D0-070516-F10_S90 Day0 0.242 0.797 0.069 0.330 0.263 0.880 0.294 1.075 >50 >50
28 1HB3-W4-110215-C7_S50e Wk4 >50 >50 >50 >50 0.161 0.457 1.716 5.854 0.492 2.348 36 1HC1-D0-070516-F11_S91 Day0 0.878 10.01 0.036 0.391 0.003 0.013 0.016 0.053 >50 >50
29 1HB3-W4-110215-G3_S63 Wk4 >50 >50 >50 >50 0.161 0.438 1.009 3.831 0.245 1.153 37 1HC1-W4-070116-B8_S30 Wk4 >50 >50 >50 >50 0.369 0.993 0.377 1.524 >50 >50
30 1HB3-W4-110215-H3_S67 Wk4 >50 >50 >50 >50 0.133 0.530 1.423 6.577 0.285 1.318 38 1HC1-W4-070516Pl2-B4_S96 Wk4 >50 >50 >50 >50 0.345 1.203 0.265 1.261 >50 >50
39 1HC1-W4-070516Pl2-G5_S11 Wk4 0.557 1.498 0.217 0.983 0.187 0.656 0.187 0.716 >50 >50
43 1HC2-D0-012016-A5_S39 Day0 0.104 0.494 0.067 0.469 0.103 0.760 0.270 2.673 0.004 0.017 40 1HC1-W4-070516Pl3-A3_S14 Wk4 >50 >50 >50 >50 0.107 0.398 0.090 0.457 >50 >50
44 1HC2-D0-012016-F5_S52 Day0 0.100 0.257 0.066 0.219 0.199 1.475 0.186 1.174 0.022 0.080 41 1HC1-W4-071216-D3_S66 Wk4 0.446 1.481 0.245 1.166 0.238 0.818 0.172 0.618 >50 >50
45 1HC2-D0-012216-C11_S66 Day0 0.023 0.068 0.016 0.047 >50 >50 0.137 1.325 0.169 0.914 42 1HC1-W4-071216-F7_S69 Wk4 >50 >50 >50 >50 0.316 0.808 0.202 0.745 >50 >50
46 1HC2-D0-012216-D1_S67 Day0 0.037 0.090 0.012 0.044 0.659 >50 0.282 7.175 0.004 0.018
47 1HC2-D0-012216-F9_S75 Day0 0.029 0.090 0.012 0.046 0.018 0.083 0.031 0.096 0.003 0.020 55 1HC3-D0-012016-F7_S31 Day0 0.150 0.531 0.027 0.104 0.637 3.571 0.588 2.107 0.002 0.008
48 1HC2-D0-012216-H10_S82 Day0 0.032 0.109 0.011 0.050 0.016 0.054 0.070 0.306 0.005 0.017 56 1HC3-D0-012016-G2_S34 Day0 0.243 0.836 0.041 0.202 0.137 1.041 0.256 1.256 0.005 0.020
49 1HC2-W4-012016-F6_S83 Wk4 >50 >50 >50 >50 0.373 6.513 0.347 1.728 <0.001 0.007 57 1HC3-D0-012216-B1_S40 Day0 0.148 0.514 0.023 0.117 2.728 42.56 0.432 2.273 0.004 0.015
50 1HC2-W4-012016-H12_S93 Wk4 >50 >50 >50 >50 0.012 0.122 0.014 0.061 <0.001 0.003 58 1HC3-D0-012216-E10_S49 Day0 0.203 0.704 0.072 0.254 0.043 0.156 0.212 0.776 0.003 0.013
51 1HC2-W4-012216-A10_S1 Wk4 >50 >50 >50 >50 0.501 5.952 0.306 3.721 0.002 0.010 59 1HC3-D0-012216-G3_S52 Day0 0.284 0.946 0.060 0.213 0.132 0.630 0.456 1.679 0.022 0.064
52 1HC2-W4-012216-A6_S95 Wk4 >50 >50 >50 >50 0.051 0.175 0.125 0.727 0.003 0.012 60 1HC3-W4-012016-G1_S19 Wk4 >50 >50 >50 >50 0.184 0.816 0.441 1.667 0.019 0.053
53 1HC2-W4-012216-E4_S9 Wk4 >50 >50 >50 >50 >50 >50 0.314 7.683 <0.001 0.008 61 1HC3-W4-012016-H5_S21 Wk4 >50 >50 5.232 >50 1.125 9.426 0.726 3.600 0.017 0.041
54 1HC2-W4-012216-G5_S14 Wk4 >50 >50 >50 >50 0.009 0.383 0.015 0.268 <0.001 0.004 62 1HC3-W4-012616-C7_S77 Wk4 >50 >50 >50 >50 0.129 0.634 0.281 1.095 0.002 0.012
63 1HC3-W4-012616-F1_S85 Wk4 >50 >50 >50 >50 0.576 5.043 0.583 2.245 0.017 0.058
65 1HD1-D0-012016-A4_S67 Day0 0.019 0.102 0.007 0.034 0.202 1.313 1.772 9.558 0.387 2.654 64 1HC3-W4-012616-G4_S89 Wk4 >50 >50 >50 >50 0.610 3.033 0.805 2.914 0.001 0.006
66 1HD1-D0-012016-D6_S73 Day0 0.008 0.038 0.004 0.016 0.048 0.248 0.399 3.241 0.114 0.534
67 1HD1-D0-012016-H4_S83 Day0 0.008 0.029 0.003 0.011 0.012 0.064 0.120 0.588 0.200 0.930 79 1HD4K-D0-061516-E3_S53 Day0 0.006 0.021 0.002 0.008 0.540 1.895 2.468 9.346 >50 >50
68 1HD1-D0-012716-B1_S14 Day0 0.014 0.066 0.005 0.026 0.018 0.116 0.076 0.681 0.396 3.731 80 1HD4K-D0-061516-F7_S57 Day0 0.006 0.025 0.005 0.020 0.280 1.298 0.526 1.968 >50 >50
69 1HD1-D0-012716-B7_S16 Day0 0.014 0.046 0.004 0.021 0.071 0.351 0.368 2.098 0.724 2.104 81 1HD4K-D0-061616Pl1-D4_S83 Day0 0.006 0.027 0.006 0.020 0.175 0.628 0.613 2.199 >50 >50
70 1HD1-W4-012016-C11_S93 Wk4 >50 >50 45.41 >50 0.074 0.350 0.355 1.751 0.404 1.817 82 1HD4K-D0-061616Pl2-A4_S53 Day0 0.005 0.017 0.003 0.011 0.167 0.580 0.404 1.434 >50 >50
71 1HD1-W4-012016-C12_S94 Wk4 >50 >50 >50 >50 0.048 0.311 0.293 1.585 0.327 1.185 83 1HD4K-D0-061616Pl2-C2_S57 Day0 0.009 0.027 0.004 0.014 0.146 0.517 0.509 1.912 >50 >50
72 1HD1-W4-012616-A6_S94 Wk4 >50 >50 25.63 >50 0.037 0.177 0.155 0.583 0.452 2.111 84 1HD4K-W4-062316Pl3-A3_S25 Wk4 >50 >50 0.064 0.557 0.123 0.354 0.559 2.772 >50 >50
73 1HD1-W4-012616-D9_S6 Wk4 >50 >50 >50 >50 0.095 0.467 0.741 4.299 0.310 1.487 85 1HD4K-W4-062316Pl3-B1_S27 Wk4 >50 >50 0.030 0.214 0.150 0.947 0.537 2.219 >50 >50
74 1HD1-W4-012616-F9_S11 Wk4 >50 >50 >50 >50 0.036 0.172 0.161 0.805 0.367 1.655 86 1HD4K-W4-062316Pl3-B9_S29 Wk4 >50 >50 0.024 0.199 0.288 0.794 1.600 7.741 >50 >50
87 1HD4K-W4-062316Pl4-A11_S47 Wk4 >50 >50 0.006 0.077 0.195 0.720 0.713 2.852 >50 >50
89 1HD5K-D0-061016-C5_S3 Day0 0.054 0.162 0.012 0.040 6.836 >50 0.204 0.733 0.409 1.476 88 1HD4K-W4-062316Pl4-A3_S44 Wk4 >50 >50 0.067 0.406 0.183 0.503 0.605 2.169 >50 >50
90 1HD5K-D0-061416Pl1-F1_S17 Day0 0.054 0.159 0.010 0.045 0.035 0.131 0.166 0.622 0.335 1.204
91 1HD5K-D0-061416Pl2-D11_S27 Day0 0.037 0.130 0.008 0.040 0.034 0.118 0.210 0.783 0.469 1.629 100 1HD6K-D0-061016-B3_S9 Day0 0.025 0.097 0.013 0.040 0.226 0.748 1.075 5.167 0.159 0.432
92 1HD5K-D0-061416Pl2-D12_S28 Day0 0.054 0.191 0.007 0.038 0.040 0.112 0.142 0.627 0.392 1.432 101 1HD6K-D0-061416-F12_S50 Day0 0.053 0.187 0.021 0.063 0.243 0.780 0.843 3.761 2.449 >50
93 1HD5K-D0-061616-F6_S42 Day0 0.046 0.123 0.013 0.055 0.042 0.117 0.158 0.783 0.440 1.463 102 1HD6K-D0-061616-C10_S24 Day0 0.032 0.117 0.018 0.069 0.228 0.783 0.656 3.371 0.130 0.359
94 1HD5K-W4-061416-A6_S32e Wk4 >50 >50 >50 >50 0.048 0.168 0.149 0.658 0.310 1.436 103 1HD6K-D0-061616-C6_S21 Day0 0.026 0.096 0.015 0.046 0.215 0.750 0.673 2.589 0.274 0.918
95 1HD5K-W4-061616-A12_S44 Wk4 >50 >50 >50 >50 0.043 0.149 0.281 0.961 0.348 1.176 104 1HD6K-W4-070516-G5_S26 Wk4 >50 >50 9.092 >50 0.184 0.839 0.653 3.452 0.108 0.375
96 1HD5K-W4-061616-C11_S49 Wk4 >50 >50 >50 >50 0.355 48.18 0.229 0.891 0.429 1.530 105 1HD6K-W8-072616-D6_S65 Wk8 >50 >50 1.539 >50 0.303 1.021 0.889 4.718 0.133 0.445
97 1HD5K-W4-061616-C12_S50 Wk4 >50 >50 >50 >50 0.040 0.158 0.316 0.886 0.420 1.135 106 1HD6K-W8-072616-F2_S69 Wk8 0.044 0.130 0.013 0.037 0.350 3.342 0.040 0.205 0.185 0.504
98 1HD5K-W4-062316-D10_S59 Wk4 >50 >50 >50 >50 0.033 0.103 0.155 0.606 0.328 1.518 107 1HD6K-W8-072616-G10_S70 Wk8 >50 >50 1.034 12.84 0.241 0.791 0.824 3.005 0.153 0.403
99 1HD5K-W4-062916-A6_S61 Wk4 >50 >50 >50 >50 0.043 0.147 0.156 0.697 0.340 1.266
108 1HD8K-D0-061616-B4_S93 Day0 0.001 0.006 0.001 0.005 0.098 0.281 0.642 3.195 >50 >50
109 1HD8K-D0-062916-A4_S69 Day0 0.007 0.024 0.028 0.100 0.017 0.048 0.146 0.664 >50 >50 75 1HD2-preinf-051916-A12_S61 pre >50 >50 >50 >50 0.005 0.018 0.050 0.210 3.358 10.96
110 1HD8K-D0-062916-A9_S72 Day0 0.002 0.016 0.013 0.037 0.057 0.166 0.474 2.447 >50 >50 76 1HD2-preinf-051916-B4_S62 pre >50 >50 2.903 >50 0.001 0.003 0.004 0.014 >50 >50
111 1HD8K-D0-062916-F6_S90 Day0 0.057 0.155 0.089 0.303 0.171 0.595 1.085 3.949 >50 >50 77 1HD2-preinf-051916-D8_S66 pre >50 >50 >50 >50 0.006 0.022 0.029 0.126 1.968 13.84
112 1HD8K-D0-062916-H6_S95 Day0 0.001 0.007 0.003 0.013 0.072 0.212 0.408 2.013 >50 >50 78 1HD2-preinf-051916-H4_S73 pre >50 >50 2.380 >50 0.001 0.004 0.005 0.019 >50 >50
113 1HD8K-W4-070116Pl3-C6_S63 Wk4 >50 >50 15.91 >50 0.197 0.922 0.570 2.858 >50 >50
114 1HD8K-W4-070116Pl3-G12_S77 Wk4 >50 >50 >50 >50 0.017 0.048 0.075 0.369 >50 >50 119 1HD9K-D0-070816-B3_S30 Day0 >50 >50 >50 >50 0.030 0.087 0.284 1.587 0.153 0.873
115 1HD8K-W4-070116Pl3-H8_S80 Wk4 >50 >50 31.84 >50 0.035 0.102 0.212 0.819 >50 >50 120 1HD9K-D0-070816-C3_S35 Day0 >50 >50 >50 >50 0.040 0.147 0.576 2.221 0.120 0.625
116 1HD8K-W4-070116Pl4-E1_S86 Wk4 >50 >50 >50 >50 0.048 0.136 0.108 0.583 >50 >50 121 1HD9K-D0-071116Pl6-A10_S86 Day0 >50 >50 >50 >50 0.011 0.034 0.111 0.401 0.159 0.827
117 1HD8K-W4-070116Pl4-E9_S87 Wk4 >50 >50 38.60 >50 0.040 0.126 0.292 1.365 >50 >50
118 1HD8K-W4-070116Pl4-F7_S89 Wk4 >50 >50 >50 >50 0.017 0.044 0.156 0.562 >50 >50
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# IDs: Number of distinct primer IDs (coverage > 10) that yielded an unambiguous majority consensus. 
Supplementary Table 7. Primer-ID deep sequencing of V3 loop (HXB2 nt 6854 - 7356)
Subject # IDs (total) Sequence motif # IDs of total
# IDs 
(total) # IDs of total
G(N/D)IR - NxS 344 100% 0 0.00%
N332 mutation 0 0% 40 13.99%
S334 mutation 0 0% 246 86.01%
D/N325 mutation 0 0% 0 0%
G(N/D)IR - NxS 370 100% 0 0.00%
N332 mutation 0 0% 95 42.60%
S334 mutation 0 0% 127 56.95%
D/N325 mutation 0 0% 1 0.45%
G(N/D)IR - NxS 622 100% 2 0.40%
N332 mutation 0 0% 220 43.65%
S334 mutation 0 0% 279 55.35%
D/N325 mutation 0 0% 3 0.60%
G(N/D)IR - NxS 125 100% 0 0.00%
N332 mutation 0 0% 82 34.02%
S334 mutation 0 0% 159 65.98%
D/N325 mutation 0 0% 0 0%
G(N/D)IR - NxS 616 100% 1 0.17%
N332 mutation 0 0% 90 15.25%
S334 mutation 0 0% 389 65.93%




























Supplementary Table 8. Comparison of sequencing methods
% # of seqs % # of seqs % # of seqs % # of seqs % # of seqs % # of seqs
NNIS - 51.72% 15 39.19% 145 44.76% 4,752 S334 N 46.43% 13 43.50% 97 49.03% 5,877
DNIS - 48.28% 14 60.81% 225 54.90% 5,828 N332 D 17.86% 5 4.04% 9 8.42% 1,009
S334 N - - - - 0.34% 36 N332 S 14.29% 4 19.28% 43 11.28% 1,352
S334 G 3.57% 1 6.28% 14 3.61% 433
Total # of seqs 29 370 10,616 S334 I 3.57% 1 1.35% 3 1.19% 143
N332 K 3.57% 1 - - 3.26% 391
D/N325 K 3.57% 1 - - 1.03% 124
N332 H 3.57% 1 - - 1.08% 130
D/N325 G 3.57% 1 - - 2.26% 271
N332 I - - 15.25% 34 2.66% 319
S334 R - - 5.83% 13 4.25% 509
N332 T - - 4.04% 9 7.71% 924
D/N325 H - - 0.45% 1 0.52% 62
DNIS - - - - - 0.56% 67
DNKS - - - - - 1.46% 175
D/N325 E - - - - 1.12% 134
KTIS K/T - - - - 0.55% 66
DKIN K/N - - - - 0.01% 1
NNIS - - - - - 1.03% 123
Total # of seqs 28 223 12,110
% # of seqs % # of seqs % # of seqs % # of seqs % # of seqs % # of seqs
DNIS - 100.00% 31 100.00% 622 100.00% 5,282 S334 N 60.71% 17 54.37% 274 70.27% 4,749
N332 K 21.43% 6 14.48% 73 14.07% 951
Total # of seqs 31 622 5,282 N332 T 10.71% 3 12.30% 62 - -
N332 S 3.57% 1 13.69% 69 15.66% 1,058
D/N325 E 3.57% 1 0.20% 1 - -
N332 I - - 1.98% 10 - -
S334 R - - 0.99% 5 - -
N332 H - - 0.79% 4 - -
N332 D - - 0.40% 2 - -
D/N325 G - - 0.40% 2 - -
DNIS - - - 0.40% 2
NNIS - - - - - 0.21% 14
Total # of seqs 28 504 6,772
% # of seqs % # of seqs % # of seqs % # of seqs % # of seqs % # of seqs
NNIS - 100.00% 32 99.19% 611 99.28% 14,707 S334 N 62.50% 15 55.08% 325 47.69% 5,212
DNIS - - - 0.32% 2 0.46% 68 D/N325 K 8.33% 2 18.64% 110 16.69% 1,824
NNLS - - - 0.49% 3 - - N332 S 4.17% 1 6.78% 40 6.36% 695
D/N325 K - - - - 0.15% 22 S334 R 8.33% 2 5.08% 30 2.32% 253
S334 R - - - - 0.11% 16 S334 G - - 4.24% 25 13.11% 1,433
N332 D 4.17% 1 4.07% 24 6.03% 659
Total # of seqs 32 616 14,813 N332 I 8.33% 2 2.03% 12 1.56% 171
S334 I - - 1.53% 9 2.42% 264
N332 T 4.17% 1 1.36% 8 0.70% 77
NNIS - - - 0.17% 1 0.04% 4
N332 H - - 0.68% 4 1.41% 154
N332 K - - 0.34% 2 1.18% 129
N332 Y - - 0.48% 53
Total # of seqs 24 590 10,928
day 0 week 4
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